查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1798926

异噁唑啉的全球市场

Isoxazoline
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 271 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球异噁唑啉市场规模将达 77 亿美元

全球异噁唑啉市场规模预计在2024年为50亿美元，到2030年将达到77亿美元，在分析期间（2024-2030年）的复合年增长率为7.7%。氟拉那（Flulanar）是本报告分析的细分市场之一，预计其复合年增长率为5.3%，到分析期结束时规模将达到26亿美元。阿福拉那（Afoxolanar）细分市场在分析期间的复合年增长率预计为9.3%。

美国市场规模估计为 14 亿美元，中国市场预计复合年增长率为 11.6%

预计到2024年，美国异噁唑啉市场规模将达14亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到16亿美元，在2024-2030年的分析期间内，复合年增长率为11.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为4.0%和7.3%。在欧洲，预计德国市场的复合年增长率为5.0%。

全球异噁唑啉市场－主要趋势与驱动因素摘要

为什么异噁唑啉在动物用药品和杀寄生虫剂开发中脱颖而出？

异噁唑啉是一类广泛用于兽医学的化合物，用于治疗和预防犬猫体外寄生虫，例如跳蚤和蜱虫。异噁唑啉类分子作为昆虫GABA和麸胺酸门控氯离子通道的选择性拮抗剂，能够干扰寄生虫的中枢神经系统，而不会对哺乳动物产生影响。其特异性高、作用时间长、全身有效，使其成为首选的局部和口服抗寄生虫药物。

这些化合物在解决老款抗寄生虫药物的抗药性问题方面尤其有效。兽药公司持续将异噁唑啉衍生物製成咀嚼锭、点滴液和注射剂，为饲主提供便利，并提高治疗顺从性。由于它们能够单剂量持续控制多种寄生虫，因此受到临床医生和宠物护理专业人士的青睐。

哪些创新和监管部门的核准正在推动产品开发？

目前正在合成新的异噁唑啉衍生物，以拓宽活性频谱、最大程度降低副作用，并解决不同年龄层和品种的安全性问题。异噁唑啉与心臟预防剂、杀线虫剂和其他昆虫生长调节剂的联合治疗正在开发中，以扩大寄生虫覆盖范围。此类联合疗法旨在简化预防方案并提高市场接受度。

全球各市场监管部门的核准增强了异噁唑啉类产品的商业性影响力。严格的品质和安全评估已认可这些化合物良好的风险-效益特性。上市后监测和现场数据持续支持其在长期兽用中的有效性和安全性。此外，伴侣动物照护领域投资的不断增加也鼓励製药公司推出新的品牌药和非专利药。

市场需求在哪里成长以及主要最终用户是谁？

伴侣动物保健产品的需求正在增长，尤其是在饲养易受跳蚤侵扰的室内宠物的家庭，以及蜱虫肆虐的地区。宠物饲主正在寻找可靠、长效且每年只需少量剂量的预防产品。兽医和动物医院是主要的处方提供者，透过零售药局和动物医院分销的管道也不断扩大。

北美和欧洲是成熟的市场，得益于较高的宠物拥有率、常规预防保健措施以及清晰的监管。亚太地区和拉丁美洲由于人们意识的提高和兽医基础设施的改善，宠物护理的采用率正在上升。在新兴的宠物照护产业，处方级抗寄生虫药物的可近性逐渐提高，进一步推动了需求。

推动异噁唑啉市场成长的因素是什么？

异噁唑啉市场的成长受到多种因素的推动，包括宠物拥有量的增加、对长效有效体外寄生虫控制的需求不断增长，以及动物用药品的不断创新。药物配方技术的进步、安全性的提高以及对多种寄生虫的广泛疗效，正在提升此类产品的吸引力。

伴侣动物诊所、宠物照护零售商和线上动物药局平台的终端使用机会不断扩大，提高了产品的可近性。针对多种动物的组合产品的开发和监管核准进一步提高了其使用量。随着寄生虫抗药性和宠物医疗保健需求的不断增长，异噁唑啉类杀寄生虫剂仍然是现代兽医预防保健的重要组成部分。

部分

化合物（氟拉拉纳、阿福拉纳、萨罗拉纳、洛蒂拉纳）；宠物类型（猫、狗）

受访公司范例

  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Hitek Animal Health
  • KRKA dd
  • Merck Animal Health（MSD AH）
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saude Animal
  • PetIQ, Inc.
  • Phibro Animal Health Corporation
  • Sogeval Laboratories
  • Syngene International Ltd.
  • Vetoquinol SA
  • Virbac
  • Zoetis Inc.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP38973

Global Isoxazoline Market to Reach US$7.7 Billion by 2030

The global market for Isoxazoline estimated at US$5.0 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Fluralaner, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Afoxolaner segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.6% CAGR

The Isoxazoline market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Isoxazoline Market - Key Trends & Drivers Summarized

Why Is Isoxazoline Gaining Ground in Animal Health and Parasiticide Development?

Isoxazoline refers to a chemical class of compounds widely used in veterinary medicine for the treatment and prevention of ectoparasites such as fleas and ticks in dogs and cats. Isoxazoline-based molecules function as selective antagonists of insect GABA- and glutamate-gated chloride channels, disrupting the central nervous system of parasites without affecting mammals. The high specificity, long duration of action, and systemic efficacy have made these compounds a preferred choice for both topical and oral parasiticide formulations.

These compounds are particularly effective in managing resistance issues that affect older antiparasitic agents. Veterinary pharmaceutical companies continue to formulate isoxazoline derivatives into chewable tablets, spot-on solutions, and injectable formats, offering convenience to pet owners and improving treatment compliance. Their utility in single-dose administration and persistent control across multiple parasite species has expanded their appeal among clinicians and pet care professionals.

What Innovations and Regulatory Approvals Are Advancing Product Development?

New derivatives of isoxazoline are being synthesized to extend spectrum of activity, minimize side effects, and address safety in different age groups and breeds. Combination therapies that pair isoxazolines with heartworm preventatives, nematocides, or other insect growth regulators are under development to provide broader parasitic coverage. These fixed-dose combinations aim to simplify preventive regimens and improve market adoption.

Regulatory approvals in various global markets have strengthened the commercial presence of isoxazoline-based products. With stringent quality and safety evaluations, these compounds have gained recognition for their favorable risk-benefit profile. Post-market surveillance and field data continue to support their efficacy and safety in long-term veterinary use. Further, rising investment in companion animal care is encouraging pharmaceutical companies to introduce new branded and generic isoxazoline formulations.

Where Is Market Demand Growing, and Who Are the Primary End-Users?

Demand is expanding in companion animal health, particularly among households with indoor pets susceptible to flea infestations and regions with endemic tick populations. Pet owners are seeking reliable, long-acting protection that requires fewer administrations per year. Veterinarians and animal hospitals are the primary prescribers, with growing distribution through retail pharmacies and veterinary clinics.

North America and Europe are mature markets, supported by high rates of pet ownership, routine preventive care practices, and regulatory clarity. Asia Pacific and Latin America are witnessing increasing adoption as awareness grows and veterinary infrastructure develops. Emerging pet care industries are gradually expanding access to prescription-grade parasiticides, further boosting demand.

What Is Driving Growth in the Isoxazoline Market?

Growth in the isoxazoline market is driven by several factors including rising pet ownership, increasing demand for long-acting and effective ectoparasite control, and expanding veterinary pharmaceutical innovation. Technological advances in drug formulation, improved safety profiles, and broader efficacy against multiple parasites are enhancing product attractiveness.

End-use expansion in companion animal clinics, pet care retail, and online veterinary pharmacy platforms is improving accessibility. Combination product development and regulatory approvals for diverse animal species are further strengthening usage. As parasite resistance and pet healthcare needs evolve, isoxazoline-based parasiticides are positioned to remain essential in modern veterinary preventive medicine.

SCOPE OF STUDY:

The report analyzes the Isoxazoline market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Chemical Compound (Fluralaner, Afoxolaner, Sarolaner, Lotilaner); Pet Type (Cat, Dog)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Hitek Animal Health
  • KRKA d.d.
  • Merck Animal Health (MSD AH)
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saude Animal
  • PetIQ, Inc.
  • Phibro Animal Health Corporation
  • Sogeval Laboratories
  • Syngene International Ltd.
  • Vetoquinol S.A.
  • Virbac
  • Zoetis Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Isoxazoline - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pet Ownership and Veterinary Care Spending Drive Demand for Isoxazoline-Based Ectoparasiticides
    • Expansion of Companion Animal Flea and Tick Treatment Segments Strengthens Role of Isoxazoline in Oral and Topical Formulations
    • OEM Innovation in Broad-Spectrum Molecules Enhances Efficacy Against Resistant Flea and Mite Populations
    • Growth in Preference for Long-Acting, Monthly Dosing Schedules Throws Spotlight on Systemic Isoxazoline Compounds
    • Increasing Regulatory Approvals for Next-Generation Isoxazolines Supports Rapid Geographic Market Entry
    • OEM Development of Palatable, Species-Specific Delivery Formats Enhances Compliance in Dogs and Cats
    • Rising Incidence of Vector-Borne Diseases in Animals Promotes Preventive Use of Isoxazoline Products
    • OEM Focus on Combination Therapies With Endoparasitic Coverage Expands Utility of Isoxazoline Molecules
    • Surge in E-Commerce Veterinary Drug Sales Supports Access to Isoxazoline-Based Products Without In-Clinic Visits
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Isoxazoline Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Isoxazoline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fluralaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fluralaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Fluralaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Afoxolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Afoxolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Afoxolaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sarolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sarolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Sarolaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lotilaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lotilaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lotilaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Dog by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • JAPAN
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • CHINA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • EUROPE
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Isoxazoline by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • FRANCE
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • GERMANY
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Isoxazoline by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • INDIA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Isoxazoline by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Isoxazoline by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • AFRICA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030

IV. COMPETITION